Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

Autor: Elizabeth R. Plimack, Peter A. Jones, Kerry S. Campbell, Hui Shen, Stephen B. Baylin, Michael J. Topper, Jean-Pierre J. Issa, David I. Quinn, Noah M. Hahn, Jozef Madzo, Woonbok Chung, Peter W. Nichols, Pooja Ghatalia, Matthew R. Zibelman, Daniel M. Geynisman, Rutika Kokate, Candice L. Schwebel, R. Katherine Alpaugh, Mahvish Tafseer, Ryan S. Burgos, Justin R. Kulchycki, Toshinori Hinoue, Eric A. Ross, Zachary Madaj, Alexander W. Macfarlane, Galen Hostetter, H. Josh Jang
Rok vydání: 2023
DOI: 10.1158/1078-0432.22587036.v1
Popis: Supplementary TablesSupplementary Table 1: Patient and tumor sample informationSupplementary Table 2: Tumor mutation burdenSupplementary Table 3: Unfiltered whole exome sequencing mutation analysisSupplementary Table 4: Filtered whole exome sequencing mutation analysisSupplementary Table 5: Immunohistochemistry scores of tumorsSupplementary Table 6: FACS panel for PBMC analysisSupplementary Table 7: Geometric mean fluorescence intensity (GMFI) from PBMC FACSSupplementary Table 8: Representativeness of Study Participants
Databáze: OpenAIRE